<DOC>
	<DOCNO>NCT02192814</DOCNO>
	<brief_summary>EP0024 Phase 3 , multicenter , open-label study evaluate safety tolerability intravenous ( iv ) lacosamide ( LCM ) . Adjunctive iv LCM therapy ( 200 mg/day 400 mg/day ) administer 5 day replacement oral LCM tablet Japanese adult partial-onset seizure .</brief_summary>
	<brief_title>Open-label Study Evaluate Safety Tolerability iv Lacosamide Japanese Adults With Partial-onset Seizures</brief_title>
	<detailed_description />
	<mesh_term>Seizures</mesh_term>
	<mesh_term>Epilepsy</mesh_term>
	<mesh_term>Lacosamide</mesh_term>
	<criteria>Subject Japanese enrol EP0009 ( NCT01832038 ) receive oral Lacosamide ( LCM ) treatment partialonset seizure enrol least 8 week Subject stable twice daily ( bid ) dosage regimen LCM 200 mg/ day 400 mg/ day , 2 week prior entry EP0024 Subject receive 3 concomitant Antiepileptic Drugs ( AEDs ) dose remain stable 2 week prior entry EP0024 Subject history kind status epilepticus within 12month period prior study entry Subject actual suicidal ideation indicate positive response ( `` Yes '' ) either Question 4 Question 5 `` Since Last Visit '' version ColumbiaSuicide Severity Rating Scale ( CSSRS )</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Lacosamide</keyword>
	<keyword>LCM</keyword>
	<keyword>Epilepsy</keyword>
	<keyword>Partial-onset seizure</keyword>
	<keyword>iv</keyword>
</DOC>